Biodistribution studies of a water-soluble radioactive metallofullerene compound have been conducted using BALB͞c mice. To this end, a sample containing Ho x @C 82 (x ‫؍‬ 1, 2) was purified and derivatized to prepare the watersoluble metallofullerol, Ho x @C 82 Since the discovery of fullerenes in 1985 (1) and the subsequent incorporation of metal atoms within their carbon cage (2), intense interest has focused on these unique molecules. Research efforts have greatly extended our knowledge of the chemical and biological properties of empty fullerenes (3; for review, see ref. 4), but comparatively little is known about endohedral metallofullerenes because of their low production yields, low solution solubilities, difficult purification, and air sensitivity (5-9). However, advances in HPLC purification procedures (5-9) and chemical derivatization (10-15) of fullerenes have recently expanded research possibilities into applications for metallofullerenes when relatively small amounts of material are required.
Since the discovery of fullerenes in 1985 (1) and the subsequent incorporation of metal atoms within their carbon cage (2) , intense interest has focused on these unique molecules. Research efforts have greatly extended our knowledge of the chemical and biological properties of empty fullerenes (3; for review, see ref. 4 ), but comparatively little is known about endohedral metallofullerenes because of their low production yields, low solution solubilities, difficult purification, and air sensitivity (5) (6) (7) (8) (9) . However, advances in HPLC purification procedures (5) (6) (7) (8) (9) and chemical derivatization (10) (11) (12) (13) (14) (15) of fullerenes have recently expanded research possibilities into applications for metallofullerenes when relatively small amounts of material are required.
One potential application for metallofullerenes is in the field of nuclear medicine. Current radiopharmaceuticals employ small quantities (nanograms to milligrams) of drugs containing specially chelated radioisotopes of metals for imaging or therapeutic applications. The chelating ligands prevent direct binding of the toxic metal ions with serum components and tissue by providing a thermodynamically stable molecular environment. A major concern with these drugs, however, is their in vivo kinetic instability, which can allow the release of small amounts of toxic radiometals (16) . It is envisioned, therefore, that metallofullerenes could provide a unique alternative to chelating compounds because of their resistance to metabolism and their high kinetic stability. Additionally, the large carbon-based surface area of fullerenes and metallofullerenes (Ϸ200 Å 2 ) facilitates the development of tissue-targeting compounds by using established metallofullerene derivative chemistry (10) (11) (12) (13) (14) (15) . Thus, the metallofullerenes may be useful as a new, more stable alternative for transporting radiometals in vivo.
Empty fullerenes have low cytotoxicity both in vitro (17) (18) (19) (20) (21) (22) and in vivo (17, (23) (24) (25) (26) , despite one report of a photosensitizing C 60 derivative (24) . In addition, empty fullerenes and their derivatives have been tested for their biodistribution, and some C 60 derivatives have shown promise as anti-HIV (27) (28) (29) (30) (31) (32) (33) (34) and anticancer (35) (36) (37) agents and as an agent to reduce reactive oxygen species (20, 21) . Dugan et al. (17, 38) have also demonstrated the usefulness of fullerene derivatives as biological freeradical scavengers in vivo. Research involving the biodistribution of fullerenes in vivo is limited to studies on C 60 and La@C 82 suspensions (23, 25) , and to three water-soluble C 60 derivatives (26, 30, 39) . All of these studies indicate rapid localization and long-term residency in the liver (Ͻ1% clearance), and one of the studies demonstrated that fullerenes are not metabolized rapidly in vivo (39) . To help optimize the biocompatibility of metallofullerenes in vivo, a published procedure for the synthesis of C 60 (OH) y (y ϭ 16) was adapted to prepare a water-soluble Ho x @C 82 (OH) y metallofullerol from Ho x @C 82 (see below). This method was chosen because (i) similar polyhydroxylated species, called stealth liposomes, have reduced recognition and uptake by the body's reticuloendotholial system (40, 41) and (ii) the reaction is straightforward and proceeds in high yield by using only milligrams of metallofullerene material.
Holmium metallofullerene was chosen because of the natural monoisotopic abundance of 165 Ho, the proven utility of 166 Ho in therapeutic nuclear medicine ( 166 Ho: t 1͞2 ϭ 26.8 h, E ␤ max ϭ 1.8 MeV) (42) (43) (44) , and the high cross section of 165 Ho, which undergoes neutron capture to produce radioactive 166 Ho ( ϭ 61.2 barn). In addition, the properties of Ho x @C 82 (x ϭ 1, 2) are now relatively well understood, having been characterized previously by laser desorption-time-of-flight mass spectrometry (LD-TOF MS), EPR spectroscopy (45, 46) , purification techniques (47) , and electrochemical studies (48) .
As a prelude to the development of a metallofullerene-based radiotracer, C 60 was found to remain structurally intact (99%) in a neutron flux of 1. (50) [x ϭ 1, 2 ¶ ; y ϭ Ϸ16 (52) ʈ ] were performed to optimize production and survivability of their radioactive analogs.
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Abbreviations: LD-TOF, laser desorption-time-of-flight; ICP, inductively coupled plasma; AE, atomic emission; NAA, neutron-activation analysis; DTPA, diethylenetriaminepentaacetate; ID, injected dose. § To whom reprint requests should be addressed. e-mail: durango@ ruf.rice.edu. ¶ Based on the LD-TOF MS of HPLC-purified holmium fullerenes used in this study (Fig. 2) , it can be seen that the sample contained both mono-and diholmium metallofullerene. Therefore, the molecular formula for these compounds has been noted with an ''x'' subscript where x ϭ 1 or 2. ʈ As a result of recent work concerning the number hydroxyl groups present for C60(OH)y, the number of hydroxyl groups on holmium metallofullerol is currently assigned as 16 (see ref. 52) , although it may well be different for a metallofullerene with a C82 cage. Exhaustive attempts to obtain mass spectrometry data for Hox@C82(OH)y by using the same techniques as in ref. 52 were unsuccessful.
After the synthesis, purification, and neutron-activation steps described above, the qualitative biodistribution of 166 Ho x @C 82 (OH) y was tested in two Sprague-Dawley rats by using a ␥-camera to monitor the 166 Ho metallofullerol radiotracer over 48 hours (50) . This preliminary study suggested that metallofullerols had the unusual property of a long residency time in the blood pool. For this reason, biodistribution and metabolism studies of a metallofullerol compound were conducted by using 166 Ho x @C 82 (OH) y in BALB͞c mice and in Fischer rats.
MATERIALS AND METHODS
Synthesis and Purification of Ho x @C 82 (x ‫؍‬ 1, 2). Holmium-doped graphite electrodes were prepared by using a previously reported method (51) . Graphite rods of 0.625 cm (0.25 inch) diameter, 15 cm (6 inch) length and 40% porosity (Poco Graphite, Decatur, TX) were placed in an evacuated chamber (Ͻ1 torr; 1 torr ϭ 133 Pa) for 10 mins. Afterward, a saturated ethanolic solution of Ho(NO 3 ) 3 ⅐xH 2 O (x ϭ 5-6; Aesar) was injected into the evacuated chamber, and the rods were submerged for 30 min. The rods were then dried in air and evacuated at room temperature for 1 h before heating them to 500°C at a rate of 1°C min Ϫ1 . The rods were then maintained at 900°C under vacuum for 5 h to convert the metal salt to Ho 2 O 3 . The resultant holmium-impregnated graphite rods indicated mass gains commensurate with a Ho:C molar ratio of 0.75:100 assuming total conversion of the holmium nitrate to Ho 2 O 3 .
Endohedral holmium metallofullerenes were synthesized in a custom-designed carbon-arc furnace at 150 torr He (J.M.A., unpublished data). Typically, three metal-impregnated graphite rods were vaporized by an electric arc during a single fullerene generation procedure. Metallofullerenes were concentrated in the resultant soot by subliming most of the empty fullerenes onto a sublimation target at 500°C for 4 h in situ. Afterward, a second vacuum sublimation was performed from 500°C to 750°C while heating at a rate of 0.5°C min Ϫ1 to collect a highly enriched metallofullerene fraction. The enriched, sublimed material was collected under anaerobic conditions and Soxhlet-extracted under argon with degassed CS 2 for 8 h. For sample storage, the CS 2 Soxhlet extract was kept frozen at 77 K under nitrogen atmosphere and in the dark. When samples were needed, the solution was thawed and the solvent was evaporated to dryness under a stream of argon.
The solid, metallofullerene-enriched material was dissolved in distilled, degassed o-xylene (Ϸ2 mg⅐ml Ϫ1 ), and filtered through a 0.22 m Acrodisc nylon filter (Fisher Scientific). Chromatographic separation of Ho x @C 82 from empty fullerene mixtures was performed under anaerobic conditions on a Hitachi L-6200A Intelligent Pump HPLC system coupled to a Hitachi L-6000 HPLC pump and two 2-liter Kontes Ultra-Ware solvent delivery tanks. Peak detection was performed by using a Hitachi model L-3000 UV-Vis photodiode array detector (200-520 nm). Data acquisition and analysis was accomplished with Hitachi Model D-6000 chromatography data system software. All injections were 2 ml and were chromatographed under anaerobic conditions using freshly distilled, degassed o-xylene (8 ml͞min, Aldrich) as the mobile phase on a Buckyprep HPLC column (10 mm ϫ 250 mm; Nacalai Tesque, Kyoto). All peaks in the resulting chromatograph ( Fig. 1 ) were collected and analyzed by LD-TOF MS to determine their chemical compositions.
After LD-TOF MS analysis (Fig. 2) , the metallofullerenecontaining fraction ( Fig. 1 ) was collected from several injections and stored in a liquid N 2 -cooled Schlenck flask under N 2 atmosphere. When needed, the samples from pooled runs were thawed, and the solvent was removed in vacuo at Ϸ50°C. The solid was then weighed and redissolved in degassed o-xylene (Ϸ2 mg⅐ml Ϫ1 ) at a standard concentration and refrozen until needed. The holmium content in the metallofullerene solutions was determined by using inductively coupled plasma atomic emission spectroscopy (ICP-AE; see below).
LD-TOF MS. Mass spectrometry was performed by using LD-TOF MS at TDA Research. Samples were deposited by solution evaporation onto a 1-cm (diameter) steel disc and evacuated to 10 Ϫ7 torr before analysis. Sample desorption and ionization was achieved by using 355 nm light from a Nd-YAG laser third harmonic. Detection was achieved by using a microchannel plate ion multiplier detector.
ICP-AE. For metals analysis, samples were digested in 50 ml of concentrated HNO 3 for 1 h in air. The sample was then evaporated to dryness and diluted to a known volume with ICP eluent solution [2% (wt͞vol) HNO 3 and 0.1% (wt͞vol) nonionic surfactant (Micron, Fisher Scientific) in deionized water]. Measurements were obtained by using a Perkin-Elmer Plasma 400 ICP-AE spectrometer with data collection software. Emission lines for all standards were determined four times, whereas the unknowns were determined eight times. After data collection, the mean of each set of readings was calculated in comparison with a blank.
Holmium ICP-AE standards were made from a 10 mg⅐ml Approximately 15 hours after irradiation, the sample envelope was removed from its graphite rabbit, and the 80.5 keV (6.2% abundance) ␥-emission of 166 Ho was measured by using a calibrated, high-purity germanium detector of 50 cm 3 (EG & G, Oak Ridge, TN). Analysis of the data was achieved by using a PC-based multichannel analyzer (Canberra Industries, Meridian, CT) Samples were counted for 300 s at a calibrated position 10 cm from the detector.
The 166 Ho number (dps) at the end of irradiation was then calculated after appropriate corrections were made for the ␥-ray intensity (0.062), detector efficiency (7.8 ϫ 10 Ϫ3 ), and nuclear decay (t 1͞2 ϭ 26.8 h). The 165 Ho number was calculated from 166 Ho activity by using the values for the reaction cross section (61.2 barn) and a saturation factor of 4.44 ϫ 10 Ϫ4 (for 1 min of irradiation).
A well-type ionization chamber was used for gross activity measurements. For biodistribution studies, an automatic ␥-counter equipped with a NaI(Tl) detector (Minaxi AutoGamma 5000, Packard) was employed.
Preparation and Purification of Ho x @C 82 (OH) y . Ho x @C 82 (OH) y was prepared via a synthesis that was a slight modification of that used for the polyhydroxylation of C 60 (53) . Derivatization was performed by preparing a greenish-gold, degassed o-xylene solution (Ϸ100 ml) containing a known mass of the postchromatography metallofullerene solid described above. This solution was then stirred for 2 h under argon atmosphere with a solution containing 5 drops of tetrabutylammonium hydroxide (TBAOH, 40% in H 2 O, Aldrich) as a phase-transfer catalyst and 5 ml of a concentrated aqueous KOH solution. After stirring for 10 min, a thick, brown film was observed on the walls of the flask. The reaction mixture was then allowed to stir for an additional 10 h in air. Afterward, the solvents were removed in vacuo at 50°C.
After solvent removal, the reaction mixture was stirred with 20 ml of H 2 O͞CH 3 OH (95%:5%) for 8 h, during which period most of the solid slowly dissolved. The supernatant was then vacuum-filtered through a no. 41 cellulose filter paper (Whatman) to obtain a golden-brown aqueous solution of pH 14. This metallofullerol solution was then passed down a Sephadex G 25-80 (Sigma) size-exclusion gel chromatography column using distilled H 2 O as the eluent. A single, colored band was eluted and collected. This solution (pH 6-7) was then filtered through a 0.22 m Teflon (Acrodisc) filter, dried, weighed, and analyzed by ICP-AE and neutron-activation analysis for Ho content. This material was then stored as a dry solid in air. Exhaustive attempts to obtain mass spectrometry data for Ho x @C 82 (OH) y by using the same techniques as for C 60 (OH) 16 (53) were unsuccessful.
Preparation of 166 Ho x @C 82 (OH) y for Biodistribution Studies. A 14.2-mg sample containing 165 Ho x @C 82 (OH) y was irradiated for 3 ϫ 5 min irradiations. Between each of the irradiation periods, the sample was kept in a holding chamber cooled by flow of air for 15 min. This procedure was used to prevent long-term sample exposure to the high-temperature conditions at the irradiation position used (Ϸ200°C). After the final irradiation, the sample was stored in a hot cell for 45 min before handling to allow decay of short-lived radioactive 28 Al (t 1͞2 ϭ 2.25 min) in the sample holder.
After irradiation, the sample was dissolved in 2 ml of distilled, deionized H 2 O. This dark brown solution was then passed through an AG 50 X4 cation exchange column (Na ϩ form, 100-200 mesh, Ϸ1-ml bed volume) to remove free Ho 3ϩ liberated by sample decomposition during irradiation. Approximately 30% of the 166 Ho passed through the column and thus was assumed to be intact metallofullerol. The column was then washed with an additional 1.6 ml of deionized H 2 O. The resulting effluent was filtered through a 0.22 m Teflon Acrodisc filter to sterilize the sample and remove colloids. Finally, the solution was diluted to 4.0 ml with Mes buffer [2- mmol͞ml, Fluka). The solution was adjusted to pH 6 by the addition of 10 l of 3 M NaOAc solution and was stirred for 10 minutes. The solution was then passed through a Chelex 100 column (Ϸ0.5-ml bed volume, pre-equilibrated with NaOAc, pH 6.0) to remove any unchelated Ho 3ϩ . The sample next was diluted to 4.0 ml by addition of 3.75 ml of Mes buffer. The sample was then assayed in a well counter calibrated for the 166 Ho activity. At intervals of 1, 4, 24, and 48 h after injection, three mice were sacrificed, and samples of their organs were harvested in the following order: muscle (thigh), bone (whole leg with marrow), skin, uterus͞ovaries, large intestine, stomach (emptied), liver, kidneys, spleen, fat (abdominal), thymus, heart, lungs, brain, and blood. Each organ was weighed, and the samples were analyzed for 166 Ho activity. The fraction of injected radioactivity was calculated relative to external standard samples, which were evaluated at the beginning and end of each experimental set of samples.
Livers of the 166 Ho x @C 82 (OH) y -injected animals at the 48-h time point were harvested, homogenized separately, suspended in 15 ml of Mes buffer, and centrifuged at 5,000 rpm for 15 minutes. After centrifugation, the extraction was repeated. The 166 Ho abundance in the pelleted material and in the extracted supernatant were then determined.
Metabolism Studies of 166 Ho x @C 82 (OH) y in Fischer Rats. The remaining 166 Ho x @C 82 (OH) y stock solution from the biodistribution studies was passed through an AG50 4X cation exchange column and diluted to 1.8 ml with aqueous Mes buffer. A 500 l (10 Ci) volume of the solution was then injected into two 12-week-old female Fischer rats through a tail vein. After administration of the metallofullerol, each rat was placed in a separate metabolism cage, where the animals' feces and urine were collected. Feces and urine samples from each rat were analyzed for 166 Ho content as described above for the mouse organs. Fig. 4 . The data demonstrate that for times Ͼ1 h after injection, 166 Ho was present in measurable levels throughout the entire body except in those tissues with limited blood flow such as the brain and fat. This long-term residency in the body (Ͼ1 h) is much longer than that observed for most metal chelates.
RESULTS AND DISCUSSION
After 4 h, the concentration of 166 Ho had dropped significantly in all organs except kidney, spleen, bone, and liver. Of these organs, only the liver and bone concentrations increased from 1 to 4 h. After 24 h, the concentration of the metallofullerol was lower in the liver and kidneys compared with the 4-h values. In contrast, there was a slow increase observed in bone concentration, with no evidence of clearance. At 48 h, the 166 Ho concentration in the liver had decreased to 15% injected dose (ID) per g. This concentration was significantly lower than the maximum liver concentration at 24% ID per g. In addition, 166 Ho concentrations had dropped to 0.36% and 3.6% ID per g in the blood pool and kidney, respectively. Therefore, the 166 Ho tracer displays slow clearance from all tissue, except for the bone, which displayed a slight increase in concentration over 48 h.
One explanation for the accumulation of 166 Ho in the liver and kidneys is that metallofullerols (or their aggregates) (55) are recognized by reticuloendothelial cells, and thus retained in the liver and spleen. Such behavior has been documented for lanthanide colloids, which give biodistribution data somewhat similar to that observed in this work (56, 57) . The present study, however, indicates that metallofullerols are quite soluble (size Ͻ0.22 m) at the concentrations administered, and that localization of 166 Ho in the spleen is significantly lower than that found for traditional technetium and gold microcolloids (58, 59) . Thus, there is a significant difference between the behavior of metallofullerols and the microcolloids. In any event, if metallofullerols eventually prove to be microcolloidal suspensions, they may improve on the properties of the colloids being examined as bone-targeting chemotherapy agents to treat leukemia, bone cancer and bone pain (56, 57) . In fact, metallofullerols may have a special utility for this purpose, because empty fullerols (60) and other polyhydroxylated compounds (61, 62) have also demonstrated a high affinity for cortical bone.
The accumulation of free (39) , followed by selective absorption by liver cells (27, 29) . It is also possible that residual metallofullerol remained physically trapped in the liver cell structure or within phagocytic cells. Future studies using longer lived metal isotopes (e.g., 170 Tm) will focus on determining the ultimate fate of the entire dose of injected metallofullerol radiotracer. Such studies will also continue to probe the possibility of metabolism of the metallofullerol cage, because the question has not been resolved unambiguously by this first study.
Holmium metallofullerols are much more evenly distributed in the body than a radiolabeled trimethylene methane derivative of (empty) C 60 , which was retained mostly in the liver (90%), with little clearance after 48 h (26). In another biodistribution study of underivatized C 60 in Swiss mice (4-5 mg͞kg), it also was revealed that Ͼ95% of the compound was retained, mostly in the liver (22) . Compared with these two studies, the metallofullerol studied here, 166 Ho x @C 82 (OH) y , displays much wider biodistribution and greater clearance. This observation offers encouragement for the future development of fullerene-based biological materials.
In the only other biodistribution study involving a metallofullerene, an insoluble suspension of 140 La@C 82 was injected directly into the heart of anaesthetized rats (25) . After 24 h, Ͼ80% of the radioactivity still present in the subjects was located in the liver and blood pool, with some retention also in the brain. In contrast, Ho x @C 82 (OH) y shows negligible accumulation in the brain after 24 h (Ͻ1% ID per g).
Metabolism Studies of 166 Ho x @C 82 (OH) y in Fischer Rats. Immediately before the metabolism study, the metallofullerol sample was passed through a cation exchange column to determine whether any free Ho 3ϩ had been liberated from the fullerol cage during the 10-h period between solution preparation and injection. Results from this study indicated that Ͻ1% of the 166 Ho 3ϩ had been released from the fullerol cage. After injection of the two Fischer rats with 166 Ho x @C 82 (OH) y , the feces and urine from the animals were collected every 24 h for 5 days. Radioisotope recovery data are summarized in Table 1 and clearly show that 166 Ho x @C 82 (OH) y exhibits its fastest clearance through the urine within 24 h. This result is consistent with the biodistribution data given herein, which shows that significant amounts of 166 Ho x @C 82 (OH) y had localized in the kidney but that the values for kidneyaccumulated 166 Ho dropped off quickly within the first 24 h. After the first day, however, Ho x @C 82 (OH) y exhibited very slow clearance from the rat (Ϸ1.5% per day), with nearly equal amounts in the feces and urine.
A complete pharmacokinetic study of C 60 -MSAD [MSAD, p,pЈ-bis(2-aminoethyl)-diphenyl-bis(monosuccinimide)] has been performed by Schinazi and coworkers (30) . In their work, the empty fullerene derivative displayed a clearance half-life of 6.8 Ϯ 1.1 h [a much faster rate than for 166 Ho x @C 82 (OH) y ]. The compound also displayed a low toxicity but no renal excretion after 24 h. The same study also demonstrated nearly 100% of the C 60 -MSAD bound to protein in vitro. This binding interaction is thought to be the primary reason that C 60 -MSAD [and now possibly Ho x @C 82 (OH) y ] is excreted slowly. Additionally, C 60 -MSAD seemed to be tolerated in rats up to 25 mg͞kg, but above this concentration, the subjects died within 5 min. This concentration is at least an order of magnitude higher than the dosage of Ho x @C 82 (OH) y used in this study, so no acute toxicity comparison can be made.
CONCLUSIONS
Biodistribution studies of 166 Ho x @C 82 (OH) y in BALB͞c mice over a 48-h period have demonstrated the feasibility of using endohedral metallofullerene compounds as radiotracers for in vivo studies of fullerene-based materials. In particular, the present studies have established that metallofullerols (i) have a blood pool residency time of over an hour with nearly total clearance from blood shortly thereafter, (ii) localize in liver but with continued slow excretion, (iii) are likely unmetabolized (at least 25%) in the liver, (iv) localize and are retained in bone, and (v) were not acutely toxic in vivo at the doses tested. Slow but steady clearance of the metallofullerol over 5 days was also noted in a metabolism study using Fischer rats. These results indicate that the clearance pathways, residency times, and tissue distribution for metallofullerols make them and other fullerol-like materials potential candidates for biomedical applications, as already suggested by Dugan and coworkers for C 60 (OH) y and C 60 [C(COOH) 2 ] 3 (17, 38) . Future efforts will undoubtedly produce more sophisticated fullerene-based materials for various biological applications, and metallofullerene radiotracers will likely continue to play a central role in elucidating their behavior in animals. 
